Piotr P. Ponikowski
Inserm
10 papers in the Anchorcite directory, published between 2010 and 2021, cited 75,415 times in total.
ORCID profileResearch topics
- Clinical practice guidelines implementation · 4 papers
- Heart Failure Treatment and Management · 4 papers
- Cardiovascular Function and Risk Factors · 3 papers
- Diabetes Treatment and Management · 3 papers
- Atrial Fibrillation Management and Outcomes · 3 papers
- Blood Pressure and Hypertension Studies · 2 papers
Frequent co-authors
- Philippe H. Kolh · 5 papers
- Stephan Windecker · 5 papers
- António Coca · 5 papers
- Athanasios John Manolis · 4 papers
- Stefan D. Anker · 4 papers
- Gregory Y.H. Lip · 4 papers
- Donna Fitzsimons · 4 papers
- John J.V. McMurray · 4 papers
Papers
- 2013 ESH/ESC Guidelines for the management of arterial hypertensionEuropean Heart Journal · 2013 · 13,739 citations
The ESH/ESC Guidelines represent the views of the ESH and ESC and were arrived at after careful consideration of the available evidence at the time they were written.Health professionals are encouraged to take them fully into account when exercising their…
- 2018 ESC/ESH Guidelines for the management of arterial hypertensionEuropean Heart Journal · 2018 · 10,970 citations
The current background information and detailed discussion of the data can be found in ESC CardioMed - Section 44 Systemic hypertension ... ... Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in selecting the best…
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine · 2019 · 7,529 citations
BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with…
- 2018 ESC/EACTS Guidelines on myocardial revascularizationEuropean Heart Journal · 2018 · 7,481 citations
The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI) ... ... Clinical practice guidelines summarize…
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEuropean Heart Journal · 2016 · 6,593 citations
The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO) ... ...…
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEP Europace · 2016 · 6,438 citations
2 Representing the European Stroke Association (ESO) ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies Reviewers can be found in the Appendix.ESC entities having participated in the development of this document: Associations: European Association for Cardiovascular Prevention and…
- 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart FailureEuropean Journal of Heart Failure · 2016 · 6,032 citations
... Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition,…
- Guidelines for the management of atrial fibrillationEuropean Heart Journal · 2010 · 5,954 citations
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1–2% of the general population. Over 6 million Europeans suffer from this arrhythmia, and its prevalence is estimated to at least double in the next 50 years as…
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine · 2020 · 5,468 citations
BACKGROUNDSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes.More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart…
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine · 2021 · 5,211 citations
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In…
Metadata from OpenAlex (CC0).